Skip to main content

Advertisement

SpringerLink
Log in

In vitro and in silico anticancer activity of amygdalin on the SK-BR-3 human breast cancer cell line

  • Original Article
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

In spite of several studies that have shown the cytotoxic effects of amygdalin on the different cancer cell lines, however, the chemopreventive potential of amygdalin on the breast cancer cell line is not completely understood. We investigated the effect of amygdalin on the cell death and the level of pro-apoptotic Bax protein and anti-apoptotic Bcl-2 protein in SK-BR-3 human breast cancer cell line. The cell viability of SK-BR-3 cells was evaluated by MTT assay in different concentration of amygdalin. The level of Bax and Bcl-2 in SK-BR-3 cells were measured by western blot analysis. For statistical analysis, One-way ANOVA was used for the comparison of Bax and Bcl-2 protein level and percent of cell viability between groups. The molecular docking studies of amygdalin within the Bcl-2 (PDB ID: 4LVT) and HER2 (PDB ID: 3RCD) active site, were performed using AutoDock 4.2.5. Amygdalin induced a significant reduction of cell viability in SK-BR-3 after 24-h treatment in a dose-dependent manner. Also, amygdalin causes an increase in pro-apoptotic Bax protein and a decrease in anti-apoptotic Bcl-2 protein expression in the SK-BR-3 cells. Molecular docking studies showed that amygdalin interacts with the active site amino acids of Bcl-2 and HER2 through hydrogen bonding and some hydrophobic interactions. Amygdalin can induce apoptotic death in SK-BR-3 cells by increasing pro-apoptotic Bax protein and decreasing anti-apoptotic Bcl-2 protein expression. The results suggest that amygdalin may be a valuable candidate for the treatment of breast cancer, especially in HER2 positive cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28(1):92–98

    Article  CAS  Google Scholar 

  2. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712

    Article  CAS  Google Scholar 

  3. Wang J, Jiang Y-F (2012) Natural compounds as anticancer agents: experimental evidence. World J Exp Med 2(3):45–57

    Article  Google Scholar 

  4. Kotecha R, Takami A, Espinoza JL (2016) Dietary phytochemicals and cancer chemoprevention: a review of the clinical evidence. Oncotarget 7(32):52517–52529

    Article  Google Scholar 

  5. Doughari JH (2012) Phytochemicals: extraction methods, basic structures and mode of action as potential chemotherapeutic agents, in phytochemicals—a global perspective of their role in nutrition and health. InTechOpen

  6. Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ (2006) Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3(5):269–280

    Article  CAS  Google Scholar 

  7. Ménard S, Tagliabue E, Campiglio M, Pupa SM (2000) Role of HER2 gene overexpression in breast carcinoma. J Cell Physiol 182(2):150–162

    Article  Google Scholar 

  8. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353(16):1659–1672

    Article  CAS  Google Scholar 

  9. Valabrega G, Montemurro F, Aglietta M (2007) Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18(6):977–984

    Article  CAS  Google Scholar 

  10. Kerr JF, Winterford CM, Harmon BV (1994) Apoptosis. Its significance in cancer and cancer therapy. Cancer 73(8):2013–2026

    Article  CAS  Google Scholar 

  11. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J et al (1997) Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275(5303):1129–1132

    Article  CAS  Google Scholar 

  12. Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle RJ (1997) Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol 139(5):1281–1292

    Article  CAS  Google Scholar 

  13. Porter AG, Jänicke RU (1999) Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6(2):99–104

    Article  CAS  Google Scholar 

  14. Tanaka R, Nitta A, Nagatsu A (2014) Application of a quantitative 1 H-NMR method for the determination of amygdalin in Persicae semen, Armeniacae semen, and Mume fructus. J Nat Med 68(1):225–230

    Article  CAS  Google Scholar 

  15. Bolarinwa IF, Orfila C, Morgan MR (2015) Determination of amygdalin in apple seeds, fresh apples and processed apple juices. Food Chem 170:437–442

    Article  CAS  Google Scholar 

  16. Lee J, Zhang G, Wood E, Rogel Castillo C, Mitchell AE (2013) Quantification of amygdalin in nonbitter, semibitter, and bitter almonds (Prunus dulcis) by UHPLC-(ESI) QqQ MS/MS. J Agric Food Chem 61(32):7754–7759

    Article  CAS  Google Scholar 

  17. Cassileth BR, Lucarelli CD (2003) Herb-drug interactions in oncology. PMPH-USA, Raleigh

    Google Scholar 

  18. Moertel CG et al (1982) A clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med 306(4):201–206

    Article  CAS  Google Scholar 

  19. Miller KW, Anderson JL, Stoewsand GS (1981) Amygdalin metabolism and effect on reproduction of rats fed apricot kernels. J Toxicol Environ Health 7(3–4):457–467

    Article  CAS  Google Scholar 

  20. Blaheta RA, Nelson K, Haferkamp A, Juengel E (2016) Amygdalin, quackery or cure? Phytomedicine 23(4):367–376

    Article  CAS  Google Scholar 

  21. Song Z, Xu X (2014) Advanced research on anti-tumor effects of amygdalin. J Cancer Res Ther 10(5):3–7

    Article  Google Scholar 

  22. Lee HM, Moon A (2016) Amygdalin regulates apoptosis and adhesion in Hs578T triple-negative breast cancer cells. Biomol Ther (Seoul) 24(1):62–66

    Article  CAS  Google Scholar 

  23. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J et al (2013) ABT-199, a potent and selective Bcl-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19(2):202–208

    Article  CAS  Google Scholar 

  24. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS et al (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30(16):2785–27891

    Article  CAS  Google Scholar 

  25. Moertel CG, Ames MM, Kovach JS, Moyer TP, Rubin JR, Tinker JH (1981) A pharmacologic and toxicological study of amygdalin. JAMA 245(6):591–594

    Article  CAS  Google Scholar 

  26. Ghoncheh M, Pournamdar Z, Salehiniya H (2016) Incidence and mortality and epidemiology of breast cancer in the world. Asian Pac J Cancer Prev 17(S3):43–46

    Article  Google Scholar 

  27. van Meerloo J, Kaspers GJ, Cloos J (2011) Cell sensitivity assays: the MTT assay. Methods Mol Biol 731:237–245

    Article  Google Scholar 

  28. Qian L, Xie B, Wang Y, Qian J (2015) Amygdalin-mediated inhibition of non-small cell lung cancer cell invasion in vitro. Int J Clin Exp Pathol 8(5):5363–5370

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Chang H-K, Shin M-S, Yang H-Y, Lee J-W, Kim Y-S, Lee M-H et al (2006) Amygdalin induces apoptosis through regulation of Bax and Bcl-2 expressions in human DU145 and LNCaP prostate cancer cells. Biol Pharm Bull 29(8):1597–1602

    Article  CAS  Google Scholar 

  30. Makarević J, Rutz J, Juengel E, Kaulfuss S, Reiter M, Tsaur I et al (2014) Amygdalin blocks bladder cancer cell growth in vitro by diminishing cyclin A and cdk2. PLoS ONE 9(8):e105590

    Article  Google Scholar 

  31. Juengel E, Thomas A, Rutz J, Makarevic J, Tsaur I, Nelson K et al (2016) Amygdalin inhibits the growth of renal cell carcinoma cells in vitro. Int J Mol Med 37(2):526–532

    Article  CAS  Google Scholar 

  32. Chen Y, Ma J, Wang F, Hu J, Cui A, Wei C et al (2013) Amygdalin induces apoptosis in human cervical cancer cell line HeLa cells. Immunopharmacol Immunotoxicol 35(1):43–51

    Article  Google Scholar 

  33. Giannetti L, Consolo U, Magnoni C, Lo Muzio L (2004) Apoptosis: escaping strategies in human skin cancer. Oncol Rep 11(2):401–405

    CAS  PubMed  Google Scholar 

  34. Gross A, McDonnell JM, Korsmeyer SJ (1999) BCL-2 family members and the mitochondria in apoptosis. Genes Dev 13(15):1899–1911

    Article  CAS  Google Scholar 

  35. Korsmeyer SJ (1999) Bcl-2 gene family and the regulation of programmed cell death. Cancer Res 59(7 Suppl):1693s–1700s

    CAS  PubMed  Google Scholar 

  36. Dorr RT, Paxinos J (1978) The current status of laetrile. Ann Intern Med 89(3):389–397

    Article  CAS  Google Scholar 

  37. Greenberg DM (1980) The case against laetrile: the fraudulent cancer remedy. Cancer 45(4):799–807

    Article  CAS  Google Scholar 

  38. Young VR, Newberne PM (1981) Vitamins and cancer prevention: issues and dilemmas. Cancer 47(5 Suppl):1226–1240

    Article  CAS  Google Scholar 

  39. Carpenter RL, Lo HW (2013) Regulation of apoptosis by HER2 in breast cancer. J Carcinog Mutagen 2013(Suppl 7):003

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This paper is issued from the thesis of Bahman Moradipoodeh and financial support was provided by Hyperlipidemia Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran (Grant No. HLRC-9602).

Author information

Authors and Affiliations

  1. Department of Clinical Biochemistry, Faculty of Medicine, Ahvaz Jundishapur University of Medical Science, Ahvaz, Iran

    Bahman Moradipoodeh

  2. Abadan School of Medical Sciences, Abadan, Iran

    Mostafa Jamalan

  3. Biotechnology Research Center, Research Institute of Petroleum Industry (RIPI), Tehran, Iran

    Majid Zeinali

  4. Department of Medicinal Chemistry, School of Pharmacy, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

    Masood Fereidoonnezhad

  5. Hyperlipidemia Research Center, Department of Clinical Biochemistry, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

    Ghorban Mohammadzadeh

Authors
  1. Bahman Moradipoodeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mostafa Jamalan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Majid Zeinali
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masood Fereidoonnezhad
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ghorban Mohammadzadeh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ghorban Mohammadzadeh.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moradipoodeh, B., Jamalan, M., Zeinali, M. et al. In vitro and in silico anticancer activity of amygdalin on the SK-BR-3 human breast cancer cell line. Mol Biol Rep 46, 6361–6370 (2019). https://doi.org/10.1007/s11033-019-05080-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-019-05080-3

Keywords

Search

Navigation